Lurdes I. Zamora

Badalona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 99 publications

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

Journal: Blood advances
Published: April 08, 2026

Different SF3B1 Mutation Hotspots Show Hematopoietic Lineage-Specific VAF Patterns and Correlate with Distinct Genetic and Prognostic Profiles in Patients with Myeloid Neoplasms.

Different SF3B1 Mutation Hotspots Show Hematopoietic Lineage-Specific VAF Patterns and Correlate with Distinct Genetic and Prognostic Profiles in Patients with Myeloid Neoplasms.

Journal: Cancers
Published: March 23, 2026

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia
Published: January 23, 2026

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

Journal: Blood advances
Published: January 20, 2026

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Journal: Leukemia
Published: October 08, 2025

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols.

Journal: Medicina clinica
Published: January 24, 2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Journal: Experimental hematology & oncology
Published: December 26, 2024

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.

Journal: Diagnostic pathology
Published: October 22, 2024

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Journal: Blood cancer journal
Published: October 17, 2024

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.

Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.

Journal: HemaSphere
Published: September 20, 2024

Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants.

Beyond myeloid neoplasms germline guidelines: Validation of the thresholds criteria in the search of germline predisposition variants.

Journal: EJHaem
Published: August 29, 2024

Quantification of Histone H1 Subtypes Using Targeted Proteomics.

Quantification of Histone H1 Subtypes Using Targeted Proteomics.

Journal: Biomolecules
Published: June 09, 2024
Showing 1-12 of 99

Last Updated: 09/26/2026